louisbrulenaudet/clinical-trials huggingface dataset:
Clinical trial NCT06609421: Egg Quality Assessment
Official title: Observational Cohort Study of Oocyte Physiology in Discarded Samples of Patients Undergoing IVF
Study type: OBSERVATIONAL
Overall status: SUSPENDED
Conditions: Infertility (IVF Patients)
Ovarian Aging
IVF
Lead sponsor: Ovom Care GmbH
Sponsor class: OTHER
First posted: 2024-09-24
Enrollment: 100
Sex: FEMALE
Standard ages: CHILD
ADULT
OLDER_ADULT
Accepts healthy volunteers: no
Observational model: COHORT
Time perspective: PROSPECTIVE
Sampling method: NON_PROBABILITY_SAMPLE
Study population: People with uteri experiencing infertility issues requiring assisted reproduction via in vitro fertilisation (IVF)/intracytoplasmic sperm injection (ICSI) or undergoing elective egg freezing.

Brief summary: The goal of this observational study is to learn about egg physiology in humans.

The main question it aims to answer is if there is an association between egg physiology and egg quality.

Discarded, unfertilised eggs and follicular fluid collected during routine egg retrieval from participants undergoing in vitro fertilisation (IVF) as part of their regular medical care along with information from participants' electronic medical records will be collected and analysed.


Eligibility criteria: Inclusion Criteria:

* Undergoing in vitro fertilisation treatment or egg freezing

Exclusion Criteria:

* No discarded, unfertilised eggs for collection

Primary outcomes:
measure: Mitochondrial physiology in the oocytes
timeFrame: Baseline time of observation which lasts between 1 and 5 hours
Secondary outcomes:
measure: Comparison of oocyte mitochondrial physiology results to clinical outcomes to assess correlation (or lack thereof)
timeFrame: As the data becomes available over the course of the participants&#39; medical treatment. E.g. From enrolment until birth of an infant
Other outcomes:
Locations:
city: London
country: United Kingdom
facility: Avenues Clinic
Study officials:
References:
citation: Brayboy LM, Oulhen N, Witmyer J, Robins J, Carson S, Wessel GM. Multidrug-resistant transport activity protects oocytes from chemotherapeutic agents and changes during oocyte maturation. Fertil Steril. 2013 Nov;100(5):1428-35. doi: 10.1016/j.fertnstert.2013.07.002. Epub 2013 Aug 13.
Clinical trial NCT05483621: Hormonal Stimulation of Spermatogenesis
Official title: Hormonal Stimulation of Spermatogenesis in Non-obstructive Azoospermia
Study type: INTERVENTIONAL
Overall status: COMPLETED
Phase: PHASE1
Conditions: Azoospermia, Nonobstructive
Lead sponsor: Egymedicalpedia
Sponsor class: INDUSTRY
First posted: 2022-08-02
Enrollment: 100
Sex: MALE
Minimum age (years): 19
Maximum age (years): 72
Standard ages: ADULT
OLDER_ADULT
Accepts healthy volunteers: no
Allocation: RANDOMIZED
Intervention model: PARALLEL
Intervention model description: to evaluate the effect of hormonal stimulation for patients with non-obstructive azoospermia
Primary purpose: TREATMENT

Brief summary: Urologists and reproductive specialists are often challenged when facing patients with severe male infertility scenarios. In particular, the treatment of men with NOA demands a deeper insight. In such cases, .

Detailed description: The hormonal stimulation of spermatogenesis is still being explored. Thus, there is still little knowledge regarding the type of patient who might benefit from medical treatment, the optimal medication,

the regimen, and the duration of treatment. In male infertility, the induction for treatment with follicle stimulating hormone (FSH) in the induction and maintenance of spermatogenesis in patient with hypogonadotopic hypogonaism. As these patients are normally azoospermic without gonadotropin stimulation and during testosterone therapy

The presence of high numbers of progressively motile and normally formed sperms in the ejaculate during exogenous gonadotropin therapy might result in the desired clinical pregnancy for many infertile couples on an experimental basis and in some places already in clinical routine. FSH preparation are also used for treatment of normogonadotopic infertile men with idiopathic impairment of spermatogemesis.

Pulstile GnRH or exogenous gonadotropins are usually used to induce spermatogenesis and promote testicular enlargement .The regimen for gonadotropin replacement includes an initial use of human chorionic gonadotropin (HCG) for 6 to 12 months and then addition of FSH or human menopausal gonadotropins (HMG) until pregnancy

Eligibility criteria: Inclusion Criteria:

* Men with primary infertility due to non-obstructive azoospermia in two seminal analysis

Exclusion Criteria:

1. Patients with non-obstructive azoospermia with normal or low level of FSH.
2. Patients with serum testosterone lower than 3 nmol/L.

Primary outcomes:
measure: Hormonal treatment
timeFrame: from baseline up to 3 months after the treatment day.
Secondary outcomes:
Other outcomes:
Locations:
city: Qinā
country: Egypt
facility: Urology department - faculty of medicine, South Valley university
Study officials:
References:
Clinical trial NCT06080321: Oral Hygiene Compliance in Orthodontic Patients Using Active Reminders
Official title: Oral Hygiene Compliance in Orthodontic Patients Using Active Reminders: A Randomized Controlled Clinical Trial
Study type: INTERVENTIONAL
Overall status: RECRUITING
Phase: NA
Conditions: Oral Hygiene
Dental Plaque
Lead sponsor: University of Alexandria
Sponsor class: OTHER
First posted: 2023-10-12
Enrollment: 100
Sex: ALL
Minimum age (years): 11
Maximum age (years): 20
Standard ages: CHILD
ADULT
Accepts healthy volunteers: no
Allocation: RANDOMIZED
Intervention model: PARALLEL
Primary purpose: PREVENTION

Brief summary: The aim of the present study will be to determine if different forms of active reminders regarding oral hygiene compliance have an influence on the level of compliance within orthodontic patients


Eligibility criteria: Inclusion Criteria:

* Subjects with a complete natural dentition.
* Patients who need to undergo orthodontic therapy using fixed appliances.
* Good oral hygiene, with no signs and symptoms of periodontal disease.
* Patients with no medical or mental problems.

Exclusion Criteria:

* Patients with health risks associated with periodontal probing.
* Syndromic patients ex; Down syndrome.
* Previous orthodontic treatment.
* Patients with carious teeth

Primary outcomes:
measure: Gingival bleeding
timeFrame: up to 6 months
measure: Gingival inflammation
timeFrame: up to 6 months
measure: Plaque accumulation
timeFrame: up to 6 months
measure: Visual examination of white spot lesions
timeFrame: up to 6 months
Secondary outcomes:
Other outcomes:
Locations:
city: Alexandria
country: Egypt
facility: Faculty of Dentistry, Alexandria University
Study officials:
affiliation: Alexandria University
name: Samar M Adel, PhD
role: PRINCIPAL_INVESTIGATOR
affiliation: Department of Orthodontics, Saveetha Dental College, Saveetha Institute of Medical and Technical Sciences, Chennai, India
name: Nikhilesh R Vaid, PhD
role: STUDY_CHAIR
affiliation: Alexandria University
name: Eiman Marzouk, PhD
role: STUDY_DIRECTOR
References:
Clinical trial NCT04326621: Effectiveness of Pressure Release Technique in Patients With Chronic Low Back Pain
Official title: Effectiveness of Pressure Release Technique in Patients With Chronic Low Back Pain
Study type: INTERVENTIONAL
Overall status: UNKNOWN
Phase: NA
Conditions: Low Back Pain
Lead sponsor: Universidad Complutense de Madrid
Sponsor class: OTHER
First posted: 2020-03-30
Enrollment: 16
Sex: ALL
Minimum age (years): 18
Standard ages: ADULT
OLDER_ADULT
Accepts healthy volunteers: no
Allocation: RANDOMIZED
Intervention model: PARALLEL
Primary purpose: TREATMENT

Brief summary: A Pressure Release Technique will be test in patient with low back pain compared to a sham


Eligibility criteria: Inclusion Criteria:

* chronic low back pain at least 6 months

Exclusion Criteria:

* hernia, neurologic pain

Primary outcomes:
measure: VAS
timeFrame: immediately after treatment
measure: VAS
timeFrame: at 6 months
Secondary outcomes:
Other outcomes:
Locations:
Study officials:
References:
Clinical trial NCT00776321: Eprotirome for the Treatment of Dyslipidemia, Efficacy and Safety 12-Week, Phase ii Study to Assess the Safety and Efficacy of KB2115 in Patients With Primary Hypercholesterolemia
Official title: A Placebo Controlled, Double Blind, Randomised, 12-Week, Phase ii Study to Assess the Safety and Efficacy of KB2115 in Patients With Primary Hypercholesterolemia
Study type: INTERVENTIONAL
Overall status: COMPLETED
Phase: PHASE2
Conditions: Primary Hypercholesterolemia
Keywords: hypercholesterolemia
dyslipidemia
thyroid
safety
Lead sponsor: Karo Bio AB
Sponsor class: INDUSTRY
First posted: 2008-10-21
Enrollment: 142
Sex: ALL
Minimum age (years): 18
Maximum age (years): 65
Standard ages: ADULT
OLDER_ADULT
Accepts healthy volunteers: no
Allocation: RANDOMIZED
Intervention model: PARALLEL
Primary purpose: PREVENTION

Brief summary: Eprotirome (KB2115) is a liver selective thyroid hormone that can induce hyperthyroidism in the liver, while an euthyroid state is preserved in the extrahepatic tissue. Eprotirome has in a clinical 2-weeks studies demonstrated pronounced reduction of independent risk factors for the development of atherosclerotic cardiovascular diseases.

The purpose of the study is to assess the efficacy and safety of KB2115 as monotherapy following 12 weeks of exposure compared to placebo. The aim of the study is to assess efficacy (LDL-cholesterol lowering effects) and safety of KB2115.


Eligibility criteria: Inclusion Criteria:

* clinical diagnosis of hypercholesterolemia

Primary outcomes:
measure: LDL cholesterol
timeFrame: Week 12
Secondary outcomes:
measure: Lipid variables, Thyroid hormone levels, Bone markers,DEXA, ECG, Echocardiography, liver enzymes
timeFrame: 12 week
Other outcomes:
Locations:
city: Huddinge
country: Sweden
facility: Jens Kristensen
Study officials:
References:
Clinical trial NCT01653821: Surgical Removal of Carotid Body in Patients With Systolic Heart Failure
Official title: Surgical Removal of Carotid Body in Patients With Systolic Heart Failure.
Study type: INTERVENTIONAL
Overall status: COMPLETED
Phase: NA
Conditions: Systolic Heart Failure
Peripheral Chemoreceptor Hypersensitivity
Keywords: carotid body
heart failure
chemoreceptor
hypersensitivity
Lead sponsor: Noblewell
Sponsor class: INDUSTRY
First posted: 2012-07-31
Enrollment: 10
Sex: ALL
Minimum age (years): 18
Standard ages: ADULT
OLDER_ADULT
Accepts healthy volunteers: no
Allocation: NA
Intervention model: SINGLE_GROUP
Primary purpose: TREATMENT

Brief summary: The aim of the study is to determine safety, tolerability and feasibility of unilateral and bilateral carotid body excision in patients with systolic heart failure and peripheral chemoreceptor hypersensitivity.


Eligibility criteria: Inclusion Criteria:

* History of heart failure class II-III according to NYHA within at least 6 months prior to inclusion
* Stable clinical state within at least 4 weeks prior to inclusion
* Subject \>= 18 years old
* Left ventricular ejection fraction ≤ 45% evaluated by transthoracic echocardiography (Simpson's method)
* Carotid body present in computer cervical angiotomography
* History of exacerbated peripheral chemoreceptor sensitivity determined as \>0.6L/min/%SpO2
* Able and willing to give written informed consent

Exclusion Criteria:

* Unstable angina pectoris, coronary attack, coronary revascularization, exacerbation of heart-failure requiring hospitalization, clinically significant infection, surgery under general anesthesia within 3 months prior to inclusion
* History of stroke, transient ischemic attack (TIA), or clinically significant chronic neurological disorder
* History of heart transplant
* Pregnancy or anticipation of pregnancy
* Hemodialysis or peritoneal dialysis patients
* Obstructive carotid atherosclerotic disease with \>50% stenosis
* Severe sleep apnea syndrome diagnosed in PSG
* COPD stage III and IV according to GOLD 2007
* Unable to perform the spiroergometric assessment
* Any significant anomaly in additional investigation which may increase the risk of study procedure

Primary outcomes:
measure: Peripheral chemosensitivity
timeFrame: 4 weeks
Secondary outcomes:
Other outcomes:
Locations:
city: Wroclaw
country: Poland
facility: Centrum Chorób Serca - Klinika Kardiologii, 4. Wojskowy Szpital Kliniczny
Study officials:
References:
citation: Niewinski P, Janczak D, Rucinski A, Jazwiec P, Sobotka PA, Engelman ZJ, Fudim M, Tubek S, Jankowska EA, Banasiak W, Hart EC, Paton JF, Ponikowski P. Carotid body removal for treatment of chronic systolic heart failure. Int J Cardiol. 2013 Oct 3;168(3):2506-9. doi: 10.1016/j.ijcard.2013.03.011. Epub 2013 Mar 29.
Clinical trial NCT02439021: Effectiveness of the New Perilaryngeal Airway in Comparison With the Laryngeal Mask Airway
Official title: Effectiveness of the New Perilaryngeal Airway (CobraPLA™) in Comparison With the Laryngeal Mask Airway (LMA™) to Improve Oropharyngeal Leak Pressure Among Obese and Overweight Patients
Study type: INTERVENTIONAL
Overall status: COMPLETED
Phase: PHASE4
Conditions: Obesity
Lead sponsor: Qazvin University Of Medical Sciences
Sponsor class: OTHER
First posted: 2015-05-08
Enrollment: 74
Sex: ALL
Minimum age (years): 18
Standard ages: ADULT
OLDER_ADULT
Accepts healthy volunteers: no
Allocation: RANDOMIZED
Intervention model: PARALLEL
Primary purpose: TREATMENT

Brief summary: The Laryngeal Mask Airway (LMA) has been used widely for different patients and found to be highly safe for adult and pediatric patients. However, the LMA has some limitations and weaknesses (e.g. more insertion attempts in 5% to 10 % of all cases. Despite the easy insertion of the LMA, it is crucial to check correct placement of the LMA airway.


Eligibility criteria: Inclusion Criteria:

* BMI between 25 to 35 kg/m2
* scheduled for surgery
* being older than 18 years
* Mallampati class I-III and BMI between 25 and 35

Exclusion Criteria:

* pregnancy
* morbid obese (BMI\>35 kg/m2)
* a known difficult airway
* gastro-oesophageal reflux
* pharyngeal pathology
* emergency operation with full stomach

Primary outcomes:
measure: Oropharyngeal leak
timeFrame: Up to 1 hours
measure: Time to intubation
timeFrame: Up to 1 hours
Secondary outcomes:
measure: successful intubation attempt
timeFrame: Up to 1 hours
measure: incidence of sore throat
timeFrame: Up to 1 hours
measure: incidence of dysphasia
timeFrame: Up to 1 hours
measure: incidence of postoperative blood staining on mask
timeFrame: Up to 1 hours
Other outcomes:
Locations:
Study officials:
affiliation: Qazvin University Of Medical Sciences
name: Amir H Pakpour, PhD
role: PRINCIPAL_INVESTIGATOR
References:
Clinical trial NCT00786721: Mitochondria and Metabolic Syndrome in a Southern California Chinese Cohort
Official title: Diffuse Optical Spectroscopy Measurement Technique is Helping Develop More Effective Diagnostic Tools and Therapeutic Regimes for Diabetes, Metabolic Syndrome and Other Mitochondrial Diseases Some Time in the Future
Study type: OBSERVATIONAL
Overall status: COMPLETED
Conditions: Metabolic Syndrome
Type 2 Diabetes Mellitus
Keywords: Mitochondria and Metabolic Syndrome
Lead sponsor: University of California, Irvine
Sponsor class: OTHER
Collaborators: name: Beckman Laser Institute University of California Irvine
First posted: 2008-11-06
Enrollment: 9
Sex: ALL
Standard ages: CHILD
ADULT
OLDER_ADULT
Accepts healthy volunteers: no
Observational model: COHORT
Time perspective: PROSPECTIVE
Sampling method: NON_PROBABILITY_SAMPLE
Study population: primary care clinic, community sample, residents in a Southern California Chinese Cohort

Brief summary: There has been increasing support for our hypothesis that mitochondrial dysfunction plays an important role in the etiology of Type 2 Diabetes Mellitus and the overlapping Metabolic Syndrome.

Detailed description: Once the mitochondrial defect(s) of these subjects has been defined, the data will be used to develop two non-invasive screening tools to detect mitochondrial defects in Diabetes Mellitus and Metabolic Syndrome patients.

The device call Diffuse Optical Spectroscopy develope at Beckman Laser Instituteis is non-invasive measurement technique, to measure the properties of the muscle tisuue and vascular activity (calf, bicep, or the brain)to evaluate the patient's metabolic status and and to assess muscle mitochondrial OXPHOS function.

Eligibility criteria: Inclusion Criteria:

* Chinese descent and have been clinically diagnosed with diabetes mellitus (DM) or have met the study criteria for metabolic syndrome (MS).

Exclusion Criteria:

* non chiness descent

Primary outcomes:
measure: Near Infrared Spectroscopy to assess muscle mitochondrial OXPHOS function.
timeFrame: 4 weeks
Secondary outcomes:
Other outcomes:
Locations:
city: Irvine
country: United States
facility: Beckman Laser Institute Medical clinic
state: California
Study officials:
affiliation: Beckman Laser Institute University of California Irvine
name: Bruce J Tromberg, PhD
role: PRINCIPAL_INVESTIGATOR
affiliation: UCI, Molecular and Mitochondrial medicine and Genetics
name: Douglas c Wallace, PhD
role: PRINCIPAL_INVESTIGATOR
References:
Clinical trial NCT00266721: Efficacy of Pancrelipase on Postprandial Belching and Bloating.
Study type: INTERVENTIONAL
Overall status: COMPLETED
Phase: PHASE3
Conditions: Postprandial Bloating
Postprandial Belching
Postprandial Eructation
Keywords: Pancrelipase
Abdominal bloating
Abdominal pain
Eructation
Lead sponsor: Minneapolis Veterans Affairs Medical Center
Sponsor class: FED
First posted: 2005-12-19
Enrollment: 45
Sex: ALL
Minimum age (years): 18
Maximum age (years): 70
Standard ages: ADULT
OLDER_ADULT
Accepts healthy volunteers: no
Allocation: RANDOMIZED
Intervention model: CROSSOVER
Primary purpose: TREATMENT

Brief summary: The hypothesis of this study is that the administration of pancrelipase with meals will benefit symptoms of post-prandial bloating, pain and eructation.

Detailed description: Subjects will complete a double-blind crossover study in which, for one week periods, they will receive two pancrelipase tablets with each of the three major meals or a similarly administered identical placebo. Three times daily, subjects will rate the severity of belching, epigastric discomfort, epigastric fullness, bloating, and nausea.

Eligibility criteria: Inclusion Criteria:

* Subjects will have either bothersome upper abdominal discomfort, bloating (feeling of abdominal distention) or belching following meals for at least 12 month's duration. Subjects must have had a normal upper gastrointestinal endoscopy and/or upper GI series during the preceding three years.

Exclusion Criteria:

* Individuals with a history suggestive of organic disease such as recent weight loss, nausea, vomiting, GERD, recent changes in bowel habits will be excluded from the study.

Primary outcomes:
measure: Abdominal bloating
measure: Abdominal pain
measure: Eructation
Secondary outcomes:
Other outcomes:
Locations:
city: Minneapolis
country: United States
facility: VAMC
state: Minnesota
Study officials:
affiliation: Minneapolis VAMC
name: Michael D Levitt, MD
role: PRINCIPAL_INVESTIGATOR
References:
Clinical trial NCT02754921: Percutaneous Dilatational Tracheostomy: Ultra-perc Versus Ciaglia Blue Dolphin
Official title: Percutaneous Dilatational Tracheostomy: Ultra-perc Single Stage Dilator Technique Versus Ciaglia Blue Dolphin Ballon Dilatation Technique for Intubated Unweanable ICU Patients
Study type: INTERVENTIONAL
Overall status: COMPLETED
Phase: NA
Conditions: ICU Patients Dependant on Mechanical Ventilation : Safest Mode of Performing Percutaneous Tracheostomy Among ICU Ventilated Unweanable Patients
Lead sponsor: Al Mouwasat Hospital
Sponsor class: OTHER
First posted: 2016-04-28
Enrollment: 60
Sex: ALL
Minimum age (years): 20
Standard ages: ADULT
OLDER_ADULT
Accepts healthy volunteers: no
Allocation: RANDOMIZED
Intervention model: PARALLEL
Primary purpose: TREATMENT

Brief summary: The aim of this study is to compare Ultra-perc single stage dilator technique with Ciaglia Blue Dolphin ballon dilatation technique for intubated unweanable ICU patients with respect to procedure difficulties and complications.

Detailed description: The investigators conducted a prospective randomized trial to compare Ultra-perc single stage dilator technique (UP) and Ciaglia Blue Dolphin ballon dilatation technique (CBD) From January 2013 to December 2015.

The investigators compared the two groups as regards Procedure difficulties including difficult dilatation, difficult tube insertion, failed tube insertion, false passage and tracheal stoma over dilatation. and Procedure complications including cardiac arrest, pneumothorax, pneumomediastinum, subcutaneous emphysema, hemorrhage and lung atelectasis.

Eligibility criteria: Inclusion Criteria:

* sepsis
* cerebrovascular accidents
* cervical cord injury
* traumatic brain injury
* post arrest and chronic obstructive pulmonary disease

Exclusion Criteria:

* patient or family refusal
* emergency tracheostomy
* distorted abnormal anatomy
* bleeding diathesis
* morbid obesity
* previous tracheostomy
* infected surgical site
* Adult respiratory distress syndrome patients requiring high positive end expiratory pressure and high oxygen demands

Primary outcomes:
measure: Procedure difficulties including difficult dilatation, difficult tube insertion, failed tube insertion, false passage and tracheal stoma over dilatation.
timeFrame: within 2 years
measure: Procedure complications including cardiac arrest, pneumothorax, pneumomediastinum, subcutaneous emphysema, hemorrhage and lung atelectasis.
timeFrame: within 2 years
Secondary outcomes:
Other outcomes:
Locations:
Study officials:
References:
citation: Cianchi G, Zagli G, Bonizzoli M, Batacchi S, Cammelli R, Biondi S, Spina R, Peris A. Comparison between single-step and balloon dilatational tracheostomy in intensive care unit: a single-centre, randomized controlled study. Br J Anaesth. 2010 Jun;104(6):728-32. doi: 10.1093/bja/aeq087. Epub 2010 Apr 21.